Jacob Elguicze, SVP and CFO at Embecta Corp. (EMBC), bought 20,000 shares at $4.67 ($93K) on 2026-08-12, disclosed to the SEC on 2026-08-13.
Embecta Corp. SVP and CFO Jacob Elguicze purchased $93,360 of stock at $4.67, marking the largest purchase of his career and a reversal after five consecutive sales. This move by a C-suite executive during a period of significant insider selling may signal confidence in the company's turnaround.
The stock has surged 65.86% over the last 30 days, but remains deeply depressed at 85.02% above its 52-week low of $2.77 and is down 63.24% over the past year.
1) Q3 2026 earnings on August 7, 2026, where the company beat expectations with a $50 million sequential revenue jump and raised adjusted EPS guidance. 2) The completion of the Owen Mumford acquisition on May 18, 2026, which supports diversification into drug delivery solutions. 3) The company's margin guidance for fiscal 2026, which was raised despite revenue falling 8.1% year-over-year.
1) The stock faces a 14.18% short interest percentage, indicating significant bearish sentiment. 2) Analysts have reset fair value estimates lower, with one estimate dropping from $15.00 to $4.00, reflecting concerns over medtech valuations and higher inflation.
Something here stands out, but not much.